| Literature DB >> 33789012 |
Placide Mbala-Kingebeni1, Catherine Pratt1, Mbusa Mutafali-Ruffin1, Matthias G Pauthner1, Faustin Bile1, Antoine Nkuba-Ndaye1, Allison Black1, Eddy Kinganda-Lusamaki1, Martin Faye1, Amuri Aziza1, Moussa M Diagne1, Daniel Mukadi1, Bailey White1, James Hadfield1, Karthik Gangavarapu1, Nella Bisento1, Donatien Kazadi1, Bibiche Nsunda1, Marceline Akonga1, Olivier Tshiani1, John Misasi1, Aurelie Ploquin1, Victor Epaso1, Emilia Sana-Paka1, Yannick Tutu Tshia N'kasar1, Fabrice Mambu1, Francois Edidi1, Meris Matondo1, Junior Bula Bula1, Boubacar Diallo1, Mory Keita1, Marie R D Belizaire1, Ibrahima S Fall1, Abdoulaye Yam1, Sabue Mulangu1, Anne W Rimion1, Elias Salfati1, Ali Torkamani1, Marc A Suchard1, Ian Crozier1, Lisa Hensley1, Andrew Rambaut1, Ousmane Faye1, Amadou Sall1, Nancy J Sullivan1, Trevor Bedford1, Kristian G Andersen1, Michael R Wiley1, Steve Ahuka-Mundeke1, Jean-Jacques Muyembe Tamfum1.
Abstract
During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).Entities:
Year: 2021 PMID： 33789012 PMCID： PMC7888312 DOI： 10.1056/NEJMoa2024670
Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245